Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer
Rachael Natrajan1, Andrew N J Tutt1,2, Christopher J Lord1,3
1The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom. Chris.Lord@icr.ac.uk rachael.natrajan@icr.ac.uk andrew.tutt@icr.ac.uk.
Cancer Discovery
|March 4, 2018
Abstract:
Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms of the disease. Cancer Discov; 8(3); 272-5. ©2018 AACRSee related article by Matissek et al., p. 336See related article by Liu et al., p. 354.
Insights
Genomic tumor composition, including gene fusions, can guide treatment for aggressive cancers. Understanding these genetic alterations helps personalize therapeutic strategies for better patient outcomes.
Area of Science:
- Genomic medicine
- Cancer genomics
- Translational oncology
Background:
- Aggressive cancers present significant therapeutic challenges.
- Tumor genomic profiling is increasingly important for treatment selection.
- Intragenic gene fusions represent a class of genomic alterations with potential therapeutic implications.
Purpose of the Study:
- To review how tumor genomic composition, specifically intragenic gene fusions, can inform treatment selection.
- To highlight the clinical relevance of genomic alterations in aggressive cancers.
- To discuss the integration of genomic data into personalized cancer therapy.
Main Methods:
- Review of recent research findings on tumor genomics and treatment response.
- Analysis of intragenic gene fusions in aggressive cancer subtypes.
- Synthesis of data linking specific genomic alterations to therapeutic vulnerabilities.
Main Results:
- Genomic profiling reveals actionable targets in aggressive cancers.
- Intragenic gene fusions are identified as potential biomarkers for targeted therapies.
- The presence of specific gene fusions correlates with treatment efficacy.
Conclusions:
- Tumor genomic composition, including intragenic gene fusions, is a critical factor in selecting effective treatments for aggressive cancers.
- Genomic-guided therapy offers a personalized approach to improve outcomes.
- Further research is needed to fully elucidate the therapeutic potential of targeting gene fusions.
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
02:45Nuclear Fusion
33.9K
The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
01:24Tagging and Fusion Proteins
8.5K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K
01:43SNAREs and Membrane Fusion
12.9K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
12.9K